All Articles

Application for Genentech’s faricimab accepted by U.S. FDA for treatment of wet AMD and DMO

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Expanding the definition of AMD

Why investigators are recognising AMD as a disease spectrum rather than a single entity.

Combined MIGS and cataract surgery option offers positive results

Retrospective review highlights the sustained efficacy of combination procedure.